Learn More
OBJECTIVE Several attributes of female reproductive history, including age at natural menopause (ANM), have been related to primary open-angle glaucoma (POAG). We assembled 18 previously reported common genetic variants that predict ANM to determine their association with ANM or POAG. METHODS Using data from the Nurses' Health Study (7,143 women), we(More)
PURPOSE OF REVIEW To evaluate relevant clinical outcomes following a transzonular intravitreal injection of a compounded triamcinolone-moxifloxacin-vancomycin (TMV) formulation for postoperative prophylaxis after cataract surgery in a retrospective review of medical records from a private practice, single-specialty ambulatory center in New Jersey, USA. (More)
PURPOSE Patients with glaucoma who do not keep their follow-up eye care appointments are at risk for developing more severe ocular disease. The primary aim of the current study was to evaluate whether the use of a patient navigator altered adherence to follow-up eye care appointments in community-versus office-based settings. PATIENTS AND METHODS Patients(More)
PURPOSE To utilize the Travoprost Dosing Aid (DA) in the assessment of patient medication adherence, while also determining whether or not altering the functionality of the DA in three randomized subject groups can reduce observer effect. METHODS Forty-five subjects were randomized into three groups: two with monitored DAs and one without monitoring. One(More)
PURPOSE To evaluate the interest of glaucoma patients and their caregivers in a smartphone-based and tablet-based glaucoma application (App), developed by the Wills Eye Glaucoma Research Center in collaboration with Drexel University. MATERIALS AND METHODS Cross-sectional survey of patients with glaucoma and their caregivers. Main outcome measures are(More)
BACKGROUND The aim of this study is to summarize the design and methodology of a prospective, longitudinal, observational cohort study to investigate how glaucoma affects patients' quality of life and visually-related function over a 4-year period. METHODS/DESIGN One hundred sixty-one (161) subjects were enrolled in this ongoing study. Patients between(More)
I n 2010, participants at the National Eye Institute-Food and Drug Administration Glaucoma Clinical Design and Endpoints Symposium (NEI-FDA) discussed the adoption of new endpoint measures for assessing glaucoma therapies in clinical trials. Currently, the FDA generally accepts IOP and visual field (VF) endpoints for evaluating new treatments for glaucoma.(More)
  • 1